Headache News

With an estimated 1 billion people affected by migraine worldwide, there is an urgent need to provide effective treatment for this debilitating disease.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

CHICAGO — COVID-19-induced hyposmia eliminated odor-induced migraine headaches in an older adult, a case study presented at the 2022 American Neurological Association’s annual meeting showed.

CHICAGO — With more than 1.5 million veterans diagnosed with headache over the past two decades, the Veterans Health Administration must improve outreach and care to address disparities, an expert said at ANA 2022.

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.

LAS VEGAS — Certain red flags can indicate that a patient’s headaches are the migraine type, Merle Diamond, MD, said at PAINWeek 2022.

Theranica Bio-electronics announced positive top-line results from a double-blind, randomized, placebo-controlled, multicenter clinical trial to evaluate efficacy and safety of Nerivio for the treatment of episodic and chronic migraine.

Premenopausal and perimenopausal women with a history of migraines were more likely to experience poor sleep vs. those who did not have a history of migraines, according to a cross-sectional study presented at the NAMS Annual Meeting.

LAS VEGAS — Rapid reduction of symptoms and pain, achieved through the most effective drug and nondrug treatments, is a key priority for patients who experience acute migraines, according to a presenter at BRAINWeek 2022.

LAS VEGAS — To address patient need, affordability and physician-assisted treatment plans, a range of prevention therapies should be offered to those with migraines, according to a presenter at BRAINWeek 2022.